(Macomics) Discovery of MACO355: a first in mechanism ligand-blocking independent LILRB1/2/3 antibody for cancer therapy
In vivo tumor growth suppression
Introduction
Macrophages populate most solid tumors in large numbers and limit effective anti-tumoral immune responses [1]. The immunoreceptor tyrosine-based inhibitory motifs (‘ITIMs’)containing leukocyte immunoglobulin-like receptors (LILR) B1 and LILRB2 are expressed on tumor associated macrophages [2]. Despite sharing multiple ligands such as major histocompatibility complex class I G (HLA-G), LILRB1 regulates phagocytosis, whereas blocking ofLILRB2 ligand binding was shown to enhance cytokine release [3]. To date, therapeutic approaches to targeting LILRB1 and LILRB2 have blocked receptor – ligand interactions to relieve ligand-mediated immune suppression. To obtain antibodies with novel and superior LILRB1/LILRB2 modulating activity, we investigated both ligand blocking and non ligand-blocking clones.
![](https://cdn.prod.website-files.com/655dd3c88278aa64954052d4/667bfe69f9a41db8dae2b154_macomics-poster-aacr2024-brgsf-his_img01.webp)
Ultimate predictive models
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our modelsScientific excellence
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in FranceCustomer-centric
Tailor-made approach to your needs
Strong emphasis on customer satisfactionCollaborative partner
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate